About Services Resources Clients Presentations & Publications Request a Proposal

Publications

 

  1. Hornberger J, Alvarado M, Chien R, Gutierrez H, Yu T, Gradishar W. Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review. JNCI 2012 July 18; 104(14):1068-79.
  2. Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J. Challenges in the Development and Reimbursement of Personalized Medicine–Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Development and Reimbursement Working Group. Value in Health (in press).
  3. de Lima Lopes G, Chien R, Hornberger J. Cost-benefit of 21-gene Breast Cancer Recurrence Score for Patients in Singapore. Breast J. 2012; (in press).
  4. Nystrom J., Hornberger J., Varadhachary G., Hornberger R., Gutierrez H., Henner W., Becker S., Amin M., Walker M. Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget, 2012 June 9.
  5. Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C. Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkins’s lymphocytic leukemia after responding to first-line rituximab plus chemotherapy. Leukemia Lymphoma, 2012 June; Vol. 53. No 6.
  6. Hornberger J, Doberne J, Chien R, Laboratory-Developed Test—SynFRAME: An Approach for Assessing Laboratory-Developed Tests Synthesized from Prior Appraisal Frameworks. Genet Test Mol Biomarkers, June 2012, 16(6): 605-614.
  7. Hornberger J, Hirth R. Financial Implications of Choice of Dialysis Type of the Revised Medicare Payment System: An Economic Analysis. Am J Kidney Disease, May 2012, epub.
  8. Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, Gutierrez H, Satram-Hoang S, Keating MJ. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 53(2): 225-34.
  9. Hornberger J, Chien R, Krebs K and Hochheise L. US Insurance Program’s Experience With a Multigene Assay for Early-Stage Breast Cancer. J Oncol Pract. 2011; e38s-e45s. Also published Am J Manag Care. 2011; 1;17(5 Spec No):e194-202.
  10. Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The Cost-Effectiveness of Bortezomib in Relapsed/Refractory Multiple Myeloma: Swedish Perspective. European Journal of Haematology 2010 Dec; 85(6)484-491.
  11. Hornberger J, Lyman G, Chien R. Economic Implications of 21-Gene Recurrence Score Assay: US Multicenter Experience. J Clin Oncol. 2010 Aug 1;28(22).
  12. Hornberger J, Simpson KN, Shewade A, Dietz B, Baran R, Podsadecki T. Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial anti-retroviral therapy. Adv Ther. 2010; Adv Ther. 2010; (11):763-73
  13. Klang S, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization. Value in Health 2010; 13.
  14. Bartlett J, Hornberger J, Shewade A, Bhor M, Rajagopalan R. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:253-68.
  15. Hornberger J, Rajagopalan R, Shewade A, Loutfy M. Cost consequences of HIV-associated lipoatrophy. AIDS Care 2009;21:664-71.
  16. Hornberger J. Review of “Electronic Health Records. Guidelines for Clinicians and Administrators.” JAMA 2009; 301:110-1.
  17. Hornberger J, Hernandez J, Clark MA, et al. Rechargeable Spinal Cord Stimulation System versus Nonrechargeable System for Patients with Failed Back Surgery Syndrome: A Cost-Consequences Analysis. Clin J Pain 2008; 24:244-52.
  18. Hornberger J, Reyes C, Valente N, et al. Economic evaluation of Rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma. 2008;49 ( 2 ):227-36
  19. Lyman G, Cosler L, Kuderer N, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007; 109:1011-8.
  20. Hornberger J, Holodniy M, Robertus K, et al. A systematic review of cost-utility analyses in HIV/AIDS. Med Decis Making 2007: 789-821.
  21. Holodniy M, Hornberger J, Rapoport D. et al. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-Naïve, HIV-1 infected U.S. veterans: 1992-2004. JAIDS 2007 Jan 1;44(1):20-9.
  22. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster in older adults. Ann Intern Med 2006; 145(5):317-25. See also Summary for Patients (p. 114) and Editorial (p. 342).
  23. Hornberger J, Torriani FJ, Dieterich DT, et al. Cost–effectiveness of peginterferon alfa‑2a (40kd) plus ribavirin in patients with HIV and hepatitis C virus co‑infection. J Clin Virology 2006; 36(4):283-91.
  24. Hornberger J, Kilby M, Wintfeld N and Green J. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Research Hum Retrovirus 2006; 22(3):240-7.
  25. Hornberger J, Farci P, Prati D, et al. The economics of treating chronic Hepatitis C patients with peginterferon alfa-2a (40KD) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepatitis 2006; 13:377-86.
  26. Hornberger J, Robertus K. Comprehensive evaluations of healthcare interventions: The realism – transparency tradeoff. Med Decis Making 2005; 25:490-2.
  27. Best J, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health 2005; 8:462-70.
  28. Hornberger J, Green J, Wintfeld N, et al. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. HIV Clinical Trials 2005; 6:92-102.
  29. Hornberger J, Cosler L and Lyman G. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node–negative, estrogen-receptor–positive, early-stage breast cancer. Am J Managed Care 2005; 11:313-24.
  30. Verma S, Maraninchi D, O’Shaughnessy J, Jamieson C, Jones S, Martín M, McKendrick J, Miles J, Twelves C, Hornberger J. Capecitabine plus docetaxel combination therapy: cost-effectiveness in anthracycline-pretreated patients with advanced breast cancer. Cancer 2005; 103:2455-65.
  31. Hornberger J, Best J. Cost-utility in the United States of rituximab plus CHOP for treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005; 103:1644-51.
  32. Groot MT, Lugtenberg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in the Netherlands. Eur J Hematology 2005; 74:194-202.
  33. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Assoc Dermatol 2004; 52(2):274-86.
  34. Wrone EM, Hornberger J, Zehnder J, et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15:420-6.
  35. Wrone EM, Hornberger J. Pharmacoeconomics of folic acid supplementation for cardiovascular disease prevention. Expert Rev. Pharmacoeconomics Outcomes Res2003; 3:89-97.
  36. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health 2003; 6:9-17.
  37. Besarab  A,  Reyes C, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Disease 2002; 40:439-46.
  38. Wrone  EM, Zehnder JL, Hornberger J et al. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 2001; 60:1106-1113.
  39. Halpern J, Brown BW, Hornberger J. The sample size for a clinical trial:  A Bayesian-Decision Theoretic Approach. Stat Med 2001; 20:841-858.
  40. Hornberger J. Introduction to Bayesian reasoning. Intl J Tech Assess Health Care 2001; 17(1):9-16.
  41. Hornberger J, Goldstein MK. Clinical Decision Support Systems: Evaluating the Evaluation. Med Decis Making 2000; 20:130-1.
  42. Gerson LB, Robbins AS, Triadafilopoulos G, Hornberger J, Garber AM. A cost-effectiveness analysis of prescribing strategies in managing gastroesophageal reflux disease. Am J Gastroenterology 2000; 95:395-407.
  43. Ruhnke GW. Wilson SR, Akamatsu T, Knouc T, Takashuma Y, Goldstein MK, Koenig BA, Hornberger J, Raffin T.  Ethical decision making and patient autonomy: A comparison of physicians and patients in Japan and the United States. Chest 2000; 118:1172-1182.
  44. Lin A, Lenert LA, Hlatky MA, McDonald KM, Olshen RA, Hornberger J. Clustering and the design of preference-assessment survey in health care. Health Serv Res 1999; 34:1033-45.
  45. McCann L, Feldman C, Hornberger J et al. Effect of intradialytic parenteral nutrition on delivered Kt/V. Am J Kidney Diseases 1999; 33:1131-5.
  46. Hornberger J. Bloch DA, Hlatky MA, Baumgartner. Patient preference in coronary revascularization.  Am Heart J 1999; 137:1153-62. (see accompanying editorial;  What kind of coronary revascularization does the average American want?  Am Heart J 1999; 137:1005-6.)
  47. Wrone E, Hornberger J. Evaluating the consequences of multidisciplinary case management for patients with chronic renal failure. Am J Med 1998; 105:546-546.
  48. Raab SS, Steiner AL, Hornberger J. The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance (ASCUS). Am J Obstet Gynecol 1998; 179:411-420.
  49. Veenstra DL. Best JH, Hornberger J, Hricik DE.  Incidence and cost of steroid side effects after renal transplantation.  Transplantation Proc 1999; 31:301-302.
  50. Veenstra DL, Best JH, Hornberger J et al.  The incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Disease 1999; 33:829-39.
  51. Lenert LA, Hornberger J. Computer-assisted quality of life Assessment for Clinical Trials. Twentieth Annual Symposium on Computer Applications in Medical Care. 1988.
  52. David I, Hornberger J, Pliskin JS. On the dilemma of preemptive kidney transplantation. Med Decis Making 1998; 18:347-348.
  53. Hornberger J, Garrison L. Response to Sacristan et al. Large databases research:  alternatives or complements to randomized trials?  Ann Intern Med 1998; 128:875.
  54. Hornberger J, Best J, Geppert J, McClellan M.  Risks and costs of end-stage renal disease after heart transplantation. Transplantation 1998; 66:1763-1770.
  55. Hornberger J.  A cost-benefit analysis of a cardiovascular disease prevention trial, Using folate supplementation as an example. Am J Publ Health 1998; 88:61-67.
  56. Hornberger J, Eghtesady P.  The cost benefit of a randomized trial to a health-care organization. Controlled Clin Trials 1998; 19:198-21.
  57. Hornberger J.  Evaluating the costs of bridging language barriers in health care. J Health Care Poor Underserved 1998; 9:S26-S39.
  58. Hornberger J, Thom D, MaCurdy TE.  Enhancing attention to patient’s concerns in primary care: A randomized controlled trial. J Gen Intern Med 1997; 12:597-606.
  59. Hornberger J, Best JH, Garrison LP. Cost-effectiveness of repeat medical procedures: Kidney transplantation as an example Med Decis Making 1997; 17:363-372.
  60. Hornberger J, Wrone E. When to base clinical policies on observational versus randomized trial data. Ann Intern Med 1997; 127(Part 2):697-703.
  61. Raab SS, Hornberger J, Raffin T.  The importance of sputum cytology in the diagnosis of lung cancer: A cost-effectiveness study. Chest 1997; 112:937-45.
  62. Raab SS, Hornberger J. The effect of patient’s risk-taking attitude on the cost effectiveness of testing strategies in the evaluation of pulmonary lesions. Chest 1997; 111:1583-90.
  63. Hornberger J, Garber AM, Jeffery J.  Mortality, hospital admissions, and medical costs of end-stage renal disease in the United States and Canada. Medical Care 1997; 35:686-700
  64. Hornberger J, Itakura H, Wilson SR.  Physician perception of methods to bridge language barriers in health care. Public Health Reports 1997; 112:64-72.
  65. Hornberger J, Ahn JH.  Deciding eligibility for transplantation when a donor kidney becomes available. Med Decis Making 1997; 17:160-70.
  66. Gabbard G, Spiegel D, Hornberger J, Lazar S.  Psychotherapy, cost effectiveness, and cost offset:  A review of the literature. Am J Psych 1997; 154:147-55.
  67. Hornberger J, Lenert L. Variation among Quality-of-Life Surveys: Theory and Practice.  Medical Care 1996; 34:DS23-33.
  68. Hornberger J, Gibson CG, Wood W, Degueldre C, Corso I, Bloch DA.  Eliminating language barriers for non-English-speaking patients. Medical Care 1996; 34:845-856.
  69. Hornberger J, Brown BW, Halpern J.  Designing cost-effective clinical trials.  Stat Med 1995; 14:2249-2259.
  70. Ahn JH, Hornberger J. Involving the patient in the cadaveric kidney transplant allocation process:  A decision-theoretic perspective. Management Sci 1996; 42:629-641.
  71. Hornberger J, Habraken H, Bloch DA.  Minimum data needed on patient preferences for accurate, efficient medical decision making. Medical Care 1995; 33:297-310.
  72. Hornberger J.  Economic consequences of alterations in the hemodialysis prescription.  Seminar Dialysis 1994; 7:299-303.
  73. Hornberger J. The hemodialysis prescription and cost effectiveness. J Am Soc Nephrol 1993; 4:1021-1027.
  74. Hornberger J. The hemodialysis prescription and quality-adjusted life expectancy. J Am Soc Nephrol 1993; 4:1004-1020.
  75. Hornberger J, Chernew M and Garber AM.  Is high flux dialysis cost effective? Intl J Tech Assess Health Care 1993; 9:85-96.
  76. Hornberger J, Chernew M, Garber AM and Petersen J.  A multivariate analysis of mortality and hospital admissions with high flux dialysis. J Am Soc Nephrol 1992; 6:1227-1237.
  77. Hornberger J, Redelmeier DR and Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45:505-512.
  78. Kabalin JN, Hornberger J. Prostate specific antigen is not excreted by the human kidney or eliminated by routine hemodialysis. Urology 1991; 37:308-310.
  79. Hornberger J, Petersen J. Atrial natriuretic peptide, renal failure, and dialysis. Semin Dialysis 1990; 3:178-182.
  80. Hornberger J, Buell SJ, Flood DG, McNeill TH, Coleman PD.  Stability of numbers but not size of mouse forebrain cholinergic neurons to 53 months.  Neurobiol Aging 1985; 6:269-275.
  81. Williams MD, Hornberger J. A quantitative method of identifying older persons at risk for increasing long term care services. J Chron Disease 1984; 37:705-711.
  82. Stowe SM, Hammond GD, Chard R, Hornberger J, Honour RC, Sposto R and Weiner JM. Monitoring clinical research:  A report from the Children's Cancer Study Group.  Am J Clin Oncol 1981; 7:557-566.